Barr already shipping generic Nolvadex 10 mg and 20 mg Tablets
POMONA, N.Y., Feb. 21, 2003 -- Barr Laboratories has begun shipping Tamoxifen Citrate, 10 mg and 20 mg Tablets, the generic equivalent of AstraZeneca's Nolvadex Tablets. Barr has just received approval for both product strengths from the FDA, following the expiration of AstraZeneca's pediatric exclusivity for its Nolvadex brand version of Tamoxifen Citrate on February 20, 2003.
The company previously distributed Tamoxifen Citrate 10 mg and 20 mg tablets under a non-exclusive supply and distribution agreement with AstraZeneca. Under this agreement, Barr purchased Tamoxifen Citrate from AstraZeneca and marketed the products with the Barr label.
Barr said that the agreement expired on August 21, 2002, and that the company is now launching its own manufactured Tamoxifen Citrate, 10 mg and 20 mg tablet products.
Tamoxifen Citrate is indicated for the treatment of metastatic breast cancer, adjuvant treatment of breast cancer, ductal carcinoma in situ, and reduction in breast cancer incidences in high-risk women.
Source: Barr Laboratories www.barrlabs.com
Posted: February 2003